摘要
病理性瘢痕是一种以成纤维细胞增殖和侵袭异常增加为特征的纤维性皮肤疾病,主要包括增生性瘢痕和瘢痕疙瘩两种类型,其发病机制十分复杂。目前,已知成纤维细胞是病理性瘢痕形成的主要效应细胞,促使代谢过程失衡导致细胞外基质的过度沉积,且成纤维细胞的异质性很大程度上决定了修复结局。因此,从成纤维细胞展开深入研究以完善病理性瘢痕形成机制和寻找抑制瘢痕形成的靶点已成为近几年的研究重点。CD26/二肽基肽酶-4(DPPⅣ)是一种分布于成纤维细胞表面的多功能Ⅱ型糖蛋白,与纤维化疾病的形成发展存在密切联系,靶向CD26/DPPⅣ药物可治疗病理性瘢痕等纤维化疾病。本文对CD26/DPPⅣ在病理性瘢痕中的致病机制和临床应用进行综述,以期为病理性瘢痕临床治疗提供参考。
Pathological scar is a kind of fibrous skin disease characterized by an abnormal increase in fibroblast proliferation and invasion,and it mainly includes hypertrophic scar and keloid,and its pathogenesis is very complicated.At present,it is known that fibroblasts are the main efector cells of pathological scar formation,which promotes the imbalance of metabolic process and leads to excessive deposition of extracellular matrix.The heterogeneity of fibroblasts largely determines the repair outcome.Therefore,in-depth study of fibroblasts to improve the mechanism of pathological scar formation and find targets to inhibit scar formation has become the focus of research in recent years.CD26/dipeptidyl peptidase-4(DPP IV)is a multifunctional typeⅡglycoprotein distributed on the surface of fibroblasts,which is closely related to the formation and development of fibrotic diseases.Drugs targeting CD26/DPP IV can treat fibrotic diseases such as pathological scar.This paper reviews the pathogenic mechanism and clinical application of CD26/DPP IV in pathological scar,in order to provide reference for clinical treatment of pathological scar.
作者
刘丰瑞
崔峪铖
游顺杰(综述)
向小燕(审校)
LIU Fengrui;CUI Yucheng;YOU Shunjie;XIANG Xiaoyan(Department of Plastic Cosmetic/Burn Surgery,Affiliated Hospital of Sichuan North Medical College,Nanchong 637000,Sichuan,China)
出处
《中国美容医学》
2026年第1期168-171,共4页
Chinese Journal of Aesthetic Medicine
基金
2022年度川北医学院附属医院科研发展计划(揭榜挂帅)项目(编号:2022JC011)。
